Navigation Links
PharmAthene Provides Update on Litigation With SIGA Technologies
Date:1/24/2011

or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law.  Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, there can be no assurance that the Company will prevail in its lawsuit against Siga, or that even if the court rules in the Company's favor, the court will award monetary damages or other remedies adequate to fully compensate the Company for its loses.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010
3. PharmAthene Announces Closing of $15 Million Public Offering
4. PharmAthene Appoints Eric I. Richman President and Chief Executive Officer
5. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
6. PharmAthene Completes Previously Announced Registered Direct Offering
7. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
8. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
11. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... New Rochelle, NY -- New guidelines on cholesterol treatment ... least double the risk of dying from atherosclerotic cardiovascular ... as do women with a similar risk profile (based ... levels). The implications of this finding for when and ... an Editorial in Journal of Men,s Health , ...
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... News) -- One of the largest studies ever conducted ... uncovered 83 new sites on chromosomes that harbor inherited ... an international team of researchers, now bring the total ... to 108. Although these schizophrenia-associated genes aren,t ... predict who will or will not develop the illness, ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... Edward G.,Rendell today issued an executive order regarding ... closed after the law,authorizing its operation expired on ... 2003, when PHC4 was allowed to "sunset",by the ... action., The Rendell administration is committed to ...
... Illinois at Chicago is one of 11 centers in ... in the Clinical Islet Transplant Consortium funded by the ... clinical studies to test new approaches to islet transplantation ... effects for adults with difficult-to-control type 1 diabetes. , ...
... to vote soon on legislation that would cut ... WASHINGTON, July 8 Seniors across,Pennsylvania are speaking ... in legislation being considered in the U.S. Senate. ... the Medicare Advantage,program in Pennsylvania alone and severely ...
... DETROIT, July 8 The Barbara Ann Karmanos,Cancer ... with Meadowbrook C,Management, LLC, to lease space and ... Michigan. The approximately 14,000 square foot,space will allow ... in Novi,and the surrounding communities, as well as ...
... cancer research, particularly in observational epidemiology studies. The ... mitigated if researchers use more exacting standards when ... in the July 8 online issue of the ... Additionally, the impact of false-positive results could be ...
... in Iron Blood Levels Associated with Decreased Cancer Risk in ... arterial disease who participated in a randomized controlled trial in ... a reduced incidence of cancer relative to men in the ... have suggested that lower levels of iron in the blood ...
Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Pennsylvania Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
For the quantitative in vitro determination of Transferrin in Serum...
Determination of Reptilase Time.Extracted venom of Bothrops atrox. 20 BU (Batroxobin unit) per vial....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: